Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Patients with active colitis or immune-mediated colitis that has not resolved to grade  or less.
Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
History of inflammatory bowel disease (Crohn's or ulcerative colitis)
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis.
Active colitis or previous immune-mediated colitis that has not resolved to grade  or less.
History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis), active bowel inflammation (e.g., diverticulitis)
Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).
History of or active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
Patients with a history of colitis.
No preexisting condition that would deter radiotherapy, eg, fistulas, severe ulcerative colitis (particularly participants currently taking sulphasalazine), Crohn's disease, prior adhesions
Any symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's disease, ulcerative colitis) that requires administration of >mg of prednisone equivalent. Lower dose steroids for conditions such as hypophysitis are allowed.
Gastrointestinal tract disease or defect or previous history of colitis.
Has evidence of colitis
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nActive or prior documented inflammatory bowel disease (e.g., Crohn`s disease, ulcerative colitis); eligibility for patients with asymptomatic and a previous diagnosis of immune or inflammatory colitis, or patients with chronic diarrhea >  month without immune or inflammatory colitis is a PI decision on an individual patient basis
Serious intercurrent medical illness which would interfere with the ability of the patient to carry out the treatment program, including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active diverticulitis
Prior diagnosis of Crohn's disease or ulcerative colitis
Have gastrointestinal illness or disorder that could affect oral absorption of AP (such as short gut syndrome, Crohn's disease, ulcerative colitis, or CTCAE grade  or greater diarrhea of any etiology at baseline).
A documented history of inflammatory bowel disease (ulcerative colitis or Crohn's disease, within three years)
History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
Gastrointestinal diseases including Crohn's disease or hemorrhagic coloproctitis.
Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis
Pre-existing Familial adenomatous polyposis, inflammatory bowel disease or ulcerative colitis
Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.
Patients with Crohn's disease or ulcerative colitis
Prior diagnosis of Crohn's disease or ulcerative colitis
Active inflammatory disease requiring immunosuppressants, including small or large intestinal inflammation such as Crohn's disease or ulcerative colitis
History of ulcerative colitis or other chronic inflammatory conditions affecting rectum (includes rectal fistula, anal stenosis)
Subjects who have a history of inflammatory bowel disease, Crohn's disease, ulcerative colitis, or Wegener's granulomatosis;
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect
History of inflammatory bowel disease (e.g., Crohnis disease, ulcerative colitis),celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with absorption, distribution, metabolism, or excretion of the IP and/or predispose the subject to an increased risk of gastrointestinal toxicity.
History of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
History of Crohn's Disease or Ulcerative Colitis
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
Participant has a history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism, or excretion of the IP and/or predispose the participant to an increased risk of gastrointestinal toxicity.
Medical history of autoimmune disease (e.g., Crohn's disease, ulcerative colitis) or other diseases requiring systemic glucocorticoid or immunosuppressive therapy.
Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative Colitis, or prior total or partial gastrectomy.
Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Any patient currently requiring or anticipated to require tumor necrosis factor (TNF) blocking agent (e.g., infliximab) therapy for diagnosis of rheumatologic disease or inflammatory bowel disease (e.g., ankylosing spondylitis, Crohn disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis or ulcerative colitis)
Diagnosis of inflammatory bowel disease (Crohn's disease or Ulcerative Colitis).
Active inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis)
Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
History of prior or currently active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI) toxicity requires prior approval from the Medical Monitor.
Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
Participants with active gastrointestinal conditions (Crohn's disease, ulcerative colitis, diverticulosis associated colitis, and Behet's disease)
Active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis)
Patient with Crohn's colitis or ulcerative colitis
Previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, ulcerative colitis or Crohn's disease.
History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the IP (INVESTIGATIONAL PRODUCT) and/or predispose the subject to an increased risk of gastrointestinal toxicity
Inflammatory bowel disease, active rectal diverticulitis, Crohn's disease affecting the rectum, anal stenosis or ulcerative colitis. (Nonactive diverticulitis and Crohn's disease not affecting the rectum are allowed)